Background: It has been suggested that histologically undetectable or 'occult' metastases in the lymphatic system could explain some recurrences. HPV DNA screening by means of the polymerase chain reaction (PCR) has been proposed as a method to detect occult metastases. This study was designed to determine the frequency of HPV DNA detection by PCR in sentinel lymph node (SN), and its relation to the clinical characteristics and outcome of women with cervical cancer.
There are about 471 000 new cases of cervical cancer worldwide each year and 233 000 deaths [1] . Human papillomavirus (HPV), and especially types 16 and 18 , is an established cause of cervical carcinoma [2, 3] .
Lymph node status is a major prognostic factor in this setting, and a decision criterion for adjuvant therapy [4] [5] [6] . Despite the lack of apparent lymph node involvement, some patients have recurrences and shorter survival [5, 7] . Holmgren et al. suggested that histologically undetectable or 'occult' metastases in the lymphatic system could explain some recurrences [8] . HPV DNA screening by means of the polymerase chain reaction (PCR) has been proposed as a method to detect occult metastases [3, 8] .
Pelvic and para-aortic lymph node dissection remains the most accurate way of assessing lymph node status in this setting but is associated with significant morbidity [7] . The sentinel lymph node (SN) procedure has emerged as a less aggressive alternative [7, 9, 10] . Moreover, serial sectioning and immunohistochemical analysis of SN can detect micrometastasis [7, 9, 10] . There are no published data on the prognostic relevance of HPV DNA detection by PCR in sentinel nodes of women with cervical cancer. This study was designed to determine the frequency of HPV DNA detection by PCR in SN, and its relation to the clinical characteristics and outcome of women with cervical cancer.
patients and methods patients
From July 2001 to September 2005, 59 patients referred to our institution with cervical cancer were included in the study. Disease stage was determined as recommended by the International Federation of Gynaecology and Obstetrics (FIGO) [11] . All patients gave their informed consent for sentinel node procedure. Follow-up of patients included a physical examination every 3 months for the first post therapeutic year then every 6 months for the four additional years. SN procedure. SN procedure was performed in accordance with previous studies using combined radiocolloid and colorimetric technique [7, 9, 12, 13] . The position of each SN relative to the major pelvic vessels, and the count rate, were recorded. histopathology and HPV detection. SN analysis was performed in accordance with previous studies [9] . In brief, SNs were cut perpendicular to the long axis. All SNs were submitted to intra-operative imprint cytology with a rapid May-Grünwald-Giemsa method. Each half-SN was sectioned at 3-mm intervals, fixed in formalin and paraffin embedded. Each 3-mm section was analysed at four additional levels of 150 lm, and four parallel sections; one was used for hematoxylin and eosin (H&E) staining, and H&E-negative sections were examined by immunohistochemistry (IHC) with an anticytokeratin antibody cocktail (Cytokeratin AE1-AE3, Dako Corporation, Glostrup, Denmark). Non-SNs were totally submitted and blocked individually following 3 mm distances and H&E staining.
Micrometastasis was defined as a single focus of metastatic disease per node, measuring no more than 2 mm. The presence of single non-cohesive tumor cells was also recorded. SNs were considered positive when they contained macrometastases, micrometastases or isolated tumor cells.
In accordance with previous studies [14, 15] ., HPV DNA was detected in the primary tumor and lymph node by E6-specific PCR. To detect HPV-16, -18, and -31 DNA, we used primer pairs spanning shorter DNA sequences of the E6 open reading frame described by Resnick et al. [14] and Baay et al. [15] . The oligonucleotides used as primers for E6 HPV-16, 18, 31 and b globin DNA were respectively: 5#-GGTCGGTGGACCGGTCGATG-3' and 5#-GCAATGTAGGTGTATCTCCA-3#, 5#-CCTTGGACGTAAATTTTTGG-3' and 5#-CACGCACACGCTTGGCAGGT-3#, 5#-GGGATTGTTACAAAGCTACC-3' and 5#-GTAGTTGAGGACAACTGAC-3#, 5#-GGAGAGCCAAGGACAGGTAC-3' and 5#-CAACTTCATCCACGTTCAACC-3#. Table 1 ). The detection rate of SN was 85% and bilateral SN were identified in 40.7% of cases. One-hundred-and ten SN were detected (mean per patient: 1.9, range 1-5).
statistical analysis
Seventy-five per cent of SN were located in the external iliac area and 9% near the obturator. All 59 women underwent systematic pelvic lymphadenectomy, and a mean of 9.3 nodes were removed per patient (range 2-18). Fifteen women underwent both laparoscopic pelvic and para-aortic lymphadenectomy, and a mean of 13.2 para-aortic nodes per patient were removed (range 4-25).
histology of lymph nodes and HPV detection in cervical tumor and lymph nodes Fifteen (25.4%) of the 59 women had at least one positive SN. Twenty (18.2%) of the 110 SN were positive. Fifty-one cervical tumors were tested for HPV DNA, and 29 (57%) were positive. HPV-16, -18 and -31 DNA was detected in 22 cases (75.9%), five cases (17.2%) and two cases (6.9%), respectively (Table 1) .
HPV DNA was detected in 10 (50%) of 20 positive SN (seven of 15 patients) and in five (5.6%) of 90 negative SN (five of 44 patients). HPV DNA was more frequent in positive SN than in negative SN (P < 0.0001). In patients with positive SN, HPV DNA was detected in six (50%) of 12 positive SN from patients with HPV-positive tumors and in two (40%) of five positive SN from patients with HPV-negative tumors (P = NS).
In patients with negative SN, HPV DNA was detected in three (13.6%) of 22 SN from patients with HPV-positive tumors and in two (11.1%) of 18 SN from patients with HPVnegative tumors (P = NS).
HPV DNA was detected in six of the 12 SN containing macrometastases, in two of the five SN containing micrometastases (H&S staining), and in two of three SN containing isolated tumor cells (P = (Table 2) . Moreover, no relation was found between HPV DNA detection in SN and clinical or histological prognostic factors (Table 3) .
Fifty-three of the 59 patients were followed up, for a mean of 31.6 months (range: 10-60). Seven patients had a recurrence, after a mean of 17 months (range: 10-26). HPV DNA had been detected in the primary cervical tumor in five (71.5%) of seven patients with recurrence, versus 22 (52%) of 42 patients without recurrence (P = NS). One (14.3%) of seven patients with recurrence had one positive SN. HPV DNA was detected in SN in one (14%) of seven patients with recurrence and in nine (19.5%) of 46 patients without recurrence (P = NS). In univariate analysis, parametrial involvement was the only factor associated with the risk of recurrence (P = 0.04).
Among the seven women with recurrences, five had had an HPV DNA-positive primary cervical tumor (HPV-16 in three, HPV-18 in two). The rate of recurrence tended to be higher in women with HPV-18 DNA in their primary cervical tumor (Table 4) .
discussion
This study shows that sentinel node metastatic status correlates with nodal HPV DNA status determined by PCR. No relation was found between clinical or histological prognostic parameters and the presence of HPV DNA in the sentinel node or the primary cervical tumor.
HPV DNA was detected in 50 and 5.6% of positive and negative SN, respectively. The frequency of sentinel node HPV positivity did not differ according to the existence of macrometastasis, micrometastasis, or isolated tumor cells.
There are no other published data on HPV DNA expression in sentinel nodes from patients with cervical cancer. However, our results are in keeping with previous studies in which the frequency of HPV DNA detection in metastatic pelvic lymph nodes, diagnosed by standard H&S staining, varied from 42 to 100% of cases [3, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Our results also confirm those of Hernadi et al. [16] and Chan et al. [17] , demonstrating the 
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relation between lymph node involvement and HPV status. In contrast, Baay et al. [18] found no relation between HPV DNA detection and lymph node status. However, these authors analysed only one node from the obturator region of each patient, whereas we found that the most common site of SN was the medial external iliac region (68%) and that only 9% of SN were located in the obturator area, in keeping with other studies [9, 19] . The low rate of negative SN with detectable HPV DNA (5.6%) contrasts somewhat with previous reports of HPV DNA detection in 23-60% of tumor-free pelvic lymph nodes. The high reported frequency of HPV DNA detection in negative lymph nodes could be explained by differences in histological analysis. Indeed, previous studies used the standard H&S technique, and this can miss some metastases detected by the SN method based on systematic multiple sectioning and immunohistochemical labeling. Indeed, most of the positive SN in our study contained micrometastases or isolated tumor cells. Hence, our results suggest that HPV DNA detection in pelvic lymph nodes might be a marker of metastatic involvement and that HPV DNA-positive lymph nodes might qualify for histological analysis similar to that applied to SN, leading to better detection of so-called 'occult' metastasis. It has been suggested that lymph nodes should not only be screened for HPV DNA, but also for HPV RNA and CK 19 mRNA, or be quantified by real-time PCR [17, 20] .
We found no relationship between SN status, and classical clinical or pathological prognostic parameters such as FIGO stage, histological grade, and lymphovascular space involvement. No relation was found either between the HPV DNA status of pelvic lymph nodes and prognostic factors. Moreover, no relation was noted between the HPV DNA status of pelvic lymph nodes and the risk of recurrence. This could be explained by the fact that nearly half the positive SN were HPV DNA-negative, and also by the limited sample size. The lack of a strict relation between HPV DNA and SN involvement could be related to elimination of viral DNA molecules by scavenger lymphocytes and to HPV clearance from lymph nodes [17, 18, 21, 22] . The prognostic significance of HPV DNA detection in pelvic lymph nodes is controversial. For Pilch et al. [23] . and Hernardi et al. [16] , lymph node HPV DNA status is a significant predictor of recurrent disease. Moreover, Burnett et al. [24] detected HPV DNA in five of six patients with recurrence, and Kobayashi et al. [25] in all nine patients with clinical relapse despite pelvic node non-involvement. In contrast, Hording et al. [26] detected HPV DNA in pelvic nodes in two of 10 patients with recurrence and in three of eight patients in remission. These discrepancies could be related to the small sample sizes.
We detected HPV DNA (mainly HPV-16) in 57% of cervical cancers, in keeping with a reported prevalence of HPV DNA in cervical cancers ranging from 48 to 100% [3, 18, 22] . Unger et al. [27] . suggested that the presence of HPV DNA in primary cervical cancer was associated with poor survival. In contrast, we found no relation between HPV DNA and the FIGO stage or other classical prognostic factors. Our data are in line with those of van Bommel et al. [6] , showing no difference in survival between women with and without HPV DNA in their cervical tumors. The high frequency of HPV-16 in our study is in line with epidemiological studies showing its predominance in Europe and North America [1] . Like Barnes et al. [28] , we found that HPV-18 tended to be associated with a high risk of recurrence: HPV-18 DNA was found in the primary tumors of two of the five patients who recurred, and in only two of the 22 patients who remained in remission. No relationship was found between HPV DNA detection in the primary cervical tumor and in the sentinel node. Indeed, HPV DNA was detected in positive SN of two of three patients with negative primary tumors. These results are in keeping with those of Füle et al. [21] , showing the lack of any close correlation between metastasis and viral detection in lymph nodes. Beyer-Finkler et al. [29] pointed out that lymph node HPV DNA might originate from disintegrating tumor cells, being conveyed passively by lymphatic flow or actively by phagocytic cells. Füle et al. showed that, in highly heterogeneous advanced-stage tumors with numerous genetic original article Annals of Oncology aberrations, the loss of HPV DNA did not affect the proliferative capacity of cell clones [21] . Our study confirms the relevance of the SN procedure for assessing lymph node status in women with cervical cancer. The detection rate (85%) was slightly lower than that obtained elsewhere with dual tracer detection [9, 30] , possibly owing to the inclusion of women with locally advanced cervical cancer in whom the detection rate is lower than in women with earlier stages [19] . However, some limitations of the present study have to be underlined such as the small sample size and the low rate of HPV-DNA detection in both primary tumors and sentinel nodes.
In conclusion, this study suggests that the combination of the sentinel node procedure and HPV DNA screening of the excised nodes might contribute to better evaluation of lymph node status in women with cervical cancer and, hence, better identification of women who have an increased risk of recurrence. Further studies with larger populations are required to evaluate the prognostic relevance of HPV DNA detection in pelvic lymph nodes and in primary cervical tumors.
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